Jakavi reduced risk of death by 52% and sustained reductions in spleen size in new three-year COMFORT-II study data - Analysis from a separate trial suggested that long-term treatment with Jakavi may stabilize or improve bone marrow f

Gilenya improved the key measures: brain volume loss, MRI lesion activity, relapse rates and disability progression - Switching to Gilenya from interferon increased the proportion of patients disease free after one year

A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients - First Phase III study showing that inhibition of HER2 pos

Gilenya resulted in almost 50% more patients being free of MS disease activity after the switch from standard interferon treatment - - Annualized relapse rate reduced by >50% after 1 year for patients who switched from standard interfero

Investigational compound LDK378 is a selective inhibitor of ALK , a target found in metastatic non-small cell lung cancer (NSCLC) - Data show 60% overall response rate in 78 patients with ALK+ NSCLC taking LDK378 at 750 mg; will serv

Lucentis recommended for approval in EU to treat patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia - - Lucentis superior to current standard of care and improves mean visual acuity b